Japan approves Alzheimer's drug developed by Eisai, Biogen

Japan's health ministry on Monday approved the manufacture and sale of a drug for Alzheimer's disease developed by Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc., paving the way for the drug to be made available for use within the year.Lecanemab, branded Leqembi, will be the first drug in Japan to both treat the underlying cause of the debilitating neurodegenerative disease and slow the progression of its symptoms."We have turned a new page in the history of Alzheimer's disease treatment," Eisai CEO Haruo Naito said in a statement.Citing the disease not only causes sign…READ FULL ARTICLE